The current immunotherapeutics have remarkably improved the outcomes for some cancer patients. However, similar success has not been observed in pancreatic cancer and other immunogenic "cold" tumors. This research topic is on the strategy to “inflame” the pancreatic tumor microenvironment. Systemic chemotherapy with gemcitabine and several locoregional treatments, for example, radiotherapy, thermal ablation, and oncolytic virus, has been shown to induce immunogenic cell death (ICD) and awakened our own immune system to activate tumor-specific T cells. This makes it possible to design a combination therapy to enhance the efficacy of immunotherapy. For this aim, it is necessary to look for more efficient ways to promote expression of cancer cell neoantigens, enhance the phagocytosis of cancer cells by antigen presenting cells, prompt the generation of tumor antigen-specific T cells and overcome the dense stroma barrier to effector immune cells infiltrating into the tumor. Therefore, this strategy could provide opportunities for immunotherapy of pancreatic cancer.
This Research Topic aims at presenting the recent advances on clinical trials of combination immunotherapy for pancreatic cancer, as well as the strategies of inducing immunogenic necrosis and reshaping tumor immune microenvironment, especially the novel modality of local interventional therapy combined with immunotherapy.
We welcome submission of Original Research, Mini Review and Review on the sub-topics below:
- Clinical trial results on combination immunotherapy for pancreatic cancer.
- Design of drug delivery systems to promote immunogenic cell death.
- Application nanoparticles to enhancing antigen capture after local oncolytic treatment.
- Activation and molecular mechanisms cancer-associated fibroblast activation after locoregional treatment.
- Other strategies to overcome dense stroma barrier to effector immune cells infiltrating into the tumor.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The current immunotherapeutics have remarkably improved the outcomes for some cancer patients. However, similar success has not been observed in pancreatic cancer and other immunogenic "cold" tumors. This research topic is on the strategy to “inflame” the pancreatic tumor microenvironment. Systemic chemotherapy with gemcitabine and several locoregional treatments, for example, radiotherapy, thermal ablation, and oncolytic virus, has been shown to induce immunogenic cell death (ICD) and awakened our own immune system to activate tumor-specific T cells. This makes it possible to design a combination therapy to enhance the efficacy of immunotherapy. For this aim, it is necessary to look for more efficient ways to promote expression of cancer cell neoantigens, enhance the phagocytosis of cancer cells by antigen presenting cells, prompt the generation of tumor antigen-specific T cells and overcome the dense stroma barrier to effector immune cells infiltrating into the tumor. Therefore, this strategy could provide opportunities for immunotherapy of pancreatic cancer.
This Research Topic aims at presenting the recent advances on clinical trials of combination immunotherapy for pancreatic cancer, as well as the strategies of inducing immunogenic necrosis and reshaping tumor immune microenvironment, especially the novel modality of local interventional therapy combined with immunotherapy.
We welcome submission of Original Research, Mini Review and Review on the sub-topics below:
- Clinical trial results on combination immunotherapy for pancreatic cancer.
- Design of drug delivery systems to promote immunogenic cell death.
- Application nanoparticles to enhancing antigen capture after local oncolytic treatment.
- Activation and molecular mechanisms cancer-associated fibroblast activation after locoregional treatment.
- Other strategies to overcome dense stroma barrier to effector immune cells infiltrating into the tumor.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
